TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9410433

Group type: EXPERIMENTAL
Intervention: Special plastic syringe
Number of subjects: 120

Group type: COMPARATOR
Intervention: Glass syringe
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional plastic syringe
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 120
Study: 8311350

Group type: EXPERIMENTAL
Intervention: urapidil (0.4 mg.kg‐1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: clonidine (2.5 micrograms.kg‐1)
Number of subjects: 20
Study: 3610991

Group type: EXPERIMENTAL
Intervention: A-only mode (auditory)
Number of subjects: 15

Group type: COMPARATOR
Intervention: V-only mode (visual)
Number of subjects: 15
Study: 31403536

Group type: EXPERIMENTAL
Intervention: 2-Octylcyanoacrylate (OCA)
Number of subjects: 44

Group type: COMPARATOR
Intervention: 5-0 Fast-Absorbing Gut (FG)
Number of subjects: 44
Study: 30786937

Group type: EXPERIMENTAL
Intervention: TCZ-QW + Pred-26
Number of subjects: 0

Group type: COMPARATOR
Intervention: PBO + Pred-26
Number of subjects: 0

Group type: COMPARATOR
Intervention: PBO + Pred-52
Number of subjects: 0
Study: 27060705

Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplement (LNS)
Number of subjects: 1391

Group type: COMPARATOR
Intervention: Multiple-micronutrient (MMN) capsules
Number of subjects: 1391

Group type: COMPARATOR
Intervention: Iron-folate (IFA) capsules
Number of subjects: 1391
Study: 25148075

Group type: EXPERIMENTAL
Intervention: Health behaviour condition
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 60
Study: 23088712

Group type: EXPERIMENTAL
Intervention: More active individuals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Less active individuals
Number of subjects: 0
Study: 22216702

Group type: EXPERIMENTAL
Intervention: Lichtenstein
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: TAPP
Number of subjects: 52
Study: 19695406

Group type: EXPERIMENTAL
Intervention: Nilotinib 400 mg BID for 15 days
Number of subjects: 23
Study: 16332945

Group type: EXPERIMENTAL
Intervention: Educational outreach visits (active group)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no educational outreach visits during study period)
Number of subjects: 54
Study: 15116826

Group type: EXPERIMENTAL
Intervention: Double indicator gloves
Number of subjects: 274

Group type: COMPARATOR
Intervention: Single surgical gloves
Number of subjects: 274
Study: 11132128

Group type: EXPERIMENTAL
Intervention: Sunscreen A (UVB: Octocrylene; UVA: Mexoryl SX, Mexoryl XL, Parsol 1789; TiO2)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Sunscreen B (UVB: Eusolex 6300, Parsol MCX, Uvinul T150, Neohelipan; UVA: Parsol 1789; TiO2)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Sunscreen C (Eusolex 6300, Parsol MCX, Uvinul T150; UVA: Parsol 1789; TiO2)
Number of subjects: 11
Study: 9447571

Group type: EXPERIMENTAL
Intervention: Self-report questionnaires
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Self-report questionnaires requiring simple ratings of specified activities
Number of subjects: 51

Group type: COMPARATOR
Intervention: Actometer (motion-sensing device)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: CFS patients
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Physical activity levels
Number of subjects: 51
Study: 8118643

Group type: EXPERIMENTAL
Intervention: Nonobese obstructive sleep apnea patients and nonobese snorers
Number of subjects: 28

Group type: COMPARATOR
Intervention: Normal male control subjects
Number of subjects: 28
Study: 3310670

Group type: EXPERIMENTAL
Intervention: 250‐mg disulfiram
Number of subjects: 605

Group type: COMPARATOR
Intervention: 1‐mg disulfiram
Number of subjects: 605

Group type: COMPARATOR
Intervention: no‐disulfiram
Number of subjects: 605
Study: 29553090

Group type: EXPERIMENTAL
Intervention: 2MACE score
Number of subjects: 3172

Group type: EXPERIMENTAL
Intervention: TIMI‐AF score
Number of subjects: 3172
Study: 27256812

Group type: EXPERIMENTAL
Intervention: Cocktail of digoxin (0.25 mg), furosemide (5 mg), metformin (500 mg), and rosuvastatin (10 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cocktail of digoxin, furosemide, metformin, and rosuvastatin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Increased doses of metformin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Increased doses of furosemide
Number of subjects: 24
Study: 25975013

Group type: EXPERIMENTAL
Intervention: Salt supplements (1/8th teaspoon salt, 750 mg) mixed in formula feeds 1 day prior to sweat testing
Number of subjects: 151

Group type: COMPARATOR
Intervention: No salt supplement (control group)
Number of subjects: 151
Study: 24151581

Group type: EXPERIMENTAL
Intervention: Acceptance of participation in surgical trial
Number of subjects: 166

Group type: COMPARATOR
Intervention: Refusal of participation in surgical trial
Number of subjects: 166
Study: 22031371

Group type: EXPERIMENTAL
Intervention: Inhaling rose essential oil
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Inhaling ylang-ylang essential oil
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (rose essence)
Number of subjects: 43
Study: 18458605

Group type: EXPERIMENTAL
Intervention: Donepezil treatment
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Combined MRI and SPECT examination
Number of subjects: 91
Study: 16473462

Group type: EXPERIMENTAL
Intervention: Local anesthetic applied overtly (expected)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Local anesthetic applied covertly (unexpected)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased dose of local anesthetic
Number of subjects: 0
Study: 14612001

Group type: EXPERIMENTAL
Intervention: Daclizumab 1 to 1.5 mg/kg on day 1 and day 5 posttransplant
Number of subjects: 34

Group type: COMPARATOR
Intervention: Methylprednisolone intraoperatively followed by Neoral monotherapy, with Cellcept for 2-4 months
Number of subjects: 34
Study: 10725290

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 659

Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 659
Study: 7866928

Group type: EXPERIMENTAL
Intervention: Triclosan-copolymer pre-brush rinse (0.03% triclosan and 0.125% copolymer)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo pre-brush rinse
Number of subjects: 0
Study: 2158794

Group type: EXPERIMENTAL
Intervention: Ordinary diet plus foods containing refined Konjac meal
Number of subjects: 110

Group type: COMPARATOR
Intervention: Ordinary diet
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Refined Konjac meal
Number of subjects: 110
Study: 7381450

Group type: EXPERIMENTAL
Intervention: Experimental condition with superimposed image pairs for 5 minutes
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control condition with separated image pairs for 5 minutes
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Experimental condition with superimposed image pairs for 2 minutes
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control condition with separated image pairs for 2 minutes
Number of subjects: 89
Study: 30817710

Group type: EXPERIMENTAL
Intervention: Multiple short-duration sprints (SS)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Multiple long-duration sprints (LS)
Number of subjects: 11
Study: 28708791

Group type: EXPERIMENTAL
Intervention: Laparoscopic total mesometrial resection (L-TMMR)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Nerve-sparing radical hysterectomy (all types)
Number of subjects: 213
Study: 26059896

Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 3565

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 3565
Study: 23454876

Group type: EXPERIMENTAL
Intervention: 4-mg nicotine lozenge
Number of subjects: 81

Group type: COMPARATOR
Intervention: Tobacco-free snuff
Number of subjects: 81
Study: 21410393

Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 19589891

Group type: EXPERIMENTAL
Intervention: Aggressive disease management (e.g., infliximab treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conservative disease management
Number of subjects: 0
Study: 16640927

Group type: EXPERIMENTAL
Intervention: Enamel matrix protein (EMP)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Physiological saline (Control)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Healthy cementum chips (Control)
Number of subjects: 39
Study: 12629338

Group type: EXPERIMENTAL
Intervention: Stented group
Number of subjects: 58

Group type: COMPARATOR
Intervention: Unstented group
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 58
Study: 10817735

Group type: EXPERIMENTAL
Intervention: Echinacea
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 9172985

Group type: EXPERIMENTAL
Intervention: Sleep hygiene measures (instructive booklet with 10 recommendations)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150

Group type: COMPARATOR
Intervention: Benzodiazepines
Number of subjects: 150
Study: 8094001

Group type: EXPERIMENTAL
Intervention: Ditiocarb
Number of subjects: 1333

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1333
Study: 3618627

Group type: EXPERIMENTAL
Intervention: Crystalline fructose (60 g) supplementation
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (no fructose supplementation)
Number of subjects: 9
Study: 29777278

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Platelet transfusion
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Increase in platelet count of 20 × 10^9/L
Number of subjects: 195
Study: 27286178

Group type: EXPERIMENTAL
Intervention: Warm water immersion (42°C) for 30 minutes, 3 times per week for 8 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Moderate-intensity exercise training (cycling at 70% HRmax) for 30 minutes, 3 times per week for 8 weeks
Number of subjects: 18
Study: 24965902

Group type: EXPERIMENTAL
Intervention: Tolvaptan 15 mg
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 22698772

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafts performed by residents (n=122)
Number of subjects: 725

Group type: COMPARATOR
Intervention: Coronary artery bypass grafts performed by attending surgeons (n=409)
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafts performed by residents
Number of subjects: 725

Group type: COMPARATOR
Intervention: Coronary artery bypass grafts performed by attending surgeons
Number of subjects: 725
Study: 20557145

Group type: EXPERIMENTAL
Intervention: Intranasal ketorolac 31.5 mg
Number of subjects: 321

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 321
Study: 18997436

Group type: EXPERIMENTAL
Intervention: TJ‐3022
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: TJ‐3023
Number of subjects: 40
Study: 16417730

Group type: EXPERIMENTAL
Intervention: CRASH protocol with 3 mg of cetrorelix and stimulation with recombinant human FSH starting on cycle day 2
Number of subjects: 36

Group type: COMPARATOR
Intervention: Preceding long protocol (control)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: CRASH protocol
Number of subjects: 36
Study: 12698130

Group type: EXPERIMENTAL
Intervention: Discectomy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Postural control measurement
Number of subjects: 20
Study: 10532103

Group type: EXPERIMENTAL
Intervention: Complex therapy including immunotherapy with epithalamin 100 mg, neoadjuvant intraarterial polychemotherapy with 5-fluorouracil 2 g/m2 and cisplatin 100 mg/m2, concurrent radiotherapy, and 4-6 courses of adjuvant polychemotherapy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Adjuvant polychemotherapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Radiation alone
Number of subjects: 100
Study: 9479793

Group type: EXPERIMENTAL
Intervention: Instant lottery ticket
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no lottery ticket)
Number of subjects: 0
Study: 1577026

Group type: EXPERIMENTAL
Intervention: Intravenous rt-PA
Number of subjects: 313

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313
Study: 4072875

Group type: EXPERIMENTAL
Intervention: Cibenzoline (130 mg twice daily and 160 mg twice daily)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Quinidine (300 mg every 6 hours and 400 mg every 6 hours)
Number of subjects: 13
Study: 29806663

Group type: EXPERIMENTAL
Intervention: Zygomatic implants
Number of subjects: 71

Group type: COMPARATOR
Intervention: Augmentation
Number of subjects: 71
Study: 24853630

Group type: EXPERIMENTAL
Intervention: Same Task condition
Number of subjects: 2

Group type: COMPARATOR
Intervention: Different Task condition
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Different Task condition (pre-switch phase)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Computer-based paradigm (Experiment 3)
Number of subjects: 2
Study: 23050508

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted atazanavir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ritonavir-sparing atazanavir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unboosted atazanavir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atazanavir
Number of subjects: 0
Study: 20522535

Group type: EXPERIMENTAL
Intervention: Spironolactone 50 mg thrice weekly after dialysis
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 18422595

Group type: COMPARATOR
Intervention: EBM alone
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: EBM + Lactodex HMF
Number of subjects: 25
Study: 16192582

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (DA)
Number of subjects: 1129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1129
Study: 12799093

Group type: EXPERIMENTAL
Intervention: quinapril
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: quinapril + hydrochlorothiazide (HCTZ)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: enalapril
Number of subjects: 134

Group type: COMPARATOR
Intervention: ACE polymorphism (II+ID vs DD)
Number of subjects: 134
Study: 10551054

Group type: EXPERIMENTAL
Intervention: Corah's Dental Anxiety Scale (DAS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Kleinknecht's Dental Fear Survey (DFS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Litt's Oral Surgery Confidence Questionnaire (OSCQ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spielberger's State‐Trait Anxiety Inventory
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prior experience with tooth extractions
Number of subjects: 0
Study: 8688268

Group type: EXPERIMENTAL
Intervention: Portex tracheal tube
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oxford tube
Number of subjects: 0
Study: 1984229

Group type: EXPERIMENTAL
Intervention: Oral antibiotic therapy (amoxicillin)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study: 6954863

Group type: EXPERIMENTAL
Intervention: Multivitamin-trace mineral supplement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30403366

Group type: EXPERIMENTAL
Intervention: Impella therapy
Number of subjects: 172
Study: 30139467

Group type: EXPERIMENTAL
Intervention: Hydration plus the AVERT system (n=292)
Number of subjects: 578

Group type: COMPARATOR
Intervention: Hydration only (n=286)
Number of subjects: 578
Study: 27426247

Group type: EXPERIMENTAL
Intervention: SMART intervention group
Number of subjects: 404

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 404
Study: 24976566

Group type: EXPERIMENTAL
Intervention: Therapeutic lifestyle modification (TLM) program, 12-week, 24-session, including individualized health monitoring, group health education, exercise, and calcium-vitamin D supplementation
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 41
Study: 22588467

Group type: EXPERIMENTAL
Intervention: Deep Inspiration Breath-Hold (DIBH)
Number of subjects: 25
Study: 20094958

Group type: EXPERIMENTAL
Intervention: Amitriptyline (mean dosage 55 mg, range: 12.5-150 mg) taken at bedtime following a self-titration protocol.
Number of subjects: 60
Study: 18242045

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine and cyclophosphamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Contraception and postmenopausal hormone replacement therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mycophenolic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rituximab and other drugs (anti-BAFF, TACI-Fc)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interferon alpha (type I) inhibition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peptide vaccination with fragments of autoantibodies or autoantigens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-TNF molecules
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complement inhibition (anti-C5)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 0
Study: 16033941

Group type: EXPERIMENTAL
Intervention: Cerebellar disease patients
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (subjects without neurologic disease)
Number of subjects: 18
Study: 12105254

Group type: EXPERIMENTAL
Intervention: Permanent dual silicone catheters (DualKT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Arterio-venous vascular accesses (AVA)
Number of subjects: 42
Study: 10452624

Group type: EXPERIMENTAL
Intervention: Combined vaccine (Haemophilus influenzae type b-tetanus toxoid conjugate vaccine with three-component acellular pertussis vaccine, diphtheria and tetanus toxoids, and inactivated poliovirus vaccine)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Separate injections (Haemophilus influenzae type b-tetanus toxoid conjugate vaccine and three-component acellular pertussis vaccine, diphtheria and tetanus toxoids, and inactivated poliovirus vaccine)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Combined vaccine
Number of subjects: 180

Group type: COMPARATOR
Intervention: Separate injections
Number of subjects: 180
Study: 8591095

Group type: EXPERIMENTAL
Intervention: Treatment with additional group work
Number of subjects: 47

Group type: COMPARATOR
Intervention: Treatment without group work
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Treatment for mothers
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Treatment for children
Number of subjects: 47
Study: 2669345

Group type: EXPERIMENTAL
Intervention: Cadexomer iodine
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard treatment (saline wet‐to‐dry compressive dressing)
Number of subjects: 75
Study: 29581214

Group type: EXPERIMENTAL
Intervention: Diastolic pressure <55 mm Hg
Number of subjects: 9093

Group type: EXPERIMENTAL
Intervention: Follow-up systolic pressure
Number of subjects: 9093

Group type: EXPERIMENTAL
Intervention: Follow-up systolic pressure in intensive arm
Number of subjects: 9093
Study: 29228792

Group type: EXPERIMENTAL
Intervention: Mixed herbal formulation (Silybum marianum, Urtica dioica, Boswellia serrata) for 90 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo for 90 days
Number of subjects: 60
Study: 25446887

Group type: EXPERIMENTAL
Intervention: Bolus intravenous (IV) calcifediol (450μg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral modified-release (MR) calcifediol (450 or 900μg)
Number of subjects: 0
Study: 22836514

Group type: EXPERIMENTAL
Intervention: 3 g PL/day
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 6 g PL/day
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 6 g PL/day + 2 g PSt/day
Number of subjects: 14
Study: 21185685

Group type: EXPERIMENTAL
Intervention: Two-session motivationally focused intervention
Number of subjects: 332

Group type: COMPARATOR
Intervention: Assessment-only condition
Number of subjects: 332
Study: 18316290

Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention (4 two-hour weekly sessions)
Number of subjects: 57
Study: 17080927

Group type: EXPERIMENTAL
Intervention: New candidate therapy for neuropathic pain
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14597641

Group type: EXPERIMENTAL
Intervention: 37.5 mg aliskiren
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: 75 mg aliskiren
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: 150 mg aliskiren
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: 300 mg aliskiren
Number of subjects: 226

Group type: COMPARATOR
Intervention: 100 mg losartan
Number of subjects: 226
Study: 10811085

Group type: EXPERIMENTAL
Intervention: PRK
Number of subjects: 220

Group type: COMPARATOR
Intervention: LASIK
Number of subjects: 220
Study: 8828996

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg nightly for 7-10 nights
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study: 1433163

Group type: EXPERIMENTAL
Intervention: Low-sodium diet (LD)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Usual diet (UD)
Number of subjects: 77
Study: 3976825

Group type: EXPERIMENTAL
Intervention: Design Copying Test (DC)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Motor Accuracy-Revised Test (MAC-R)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Japan-born children
Number of subjects: 180
Study: 31463952

Group type: COMPARATOR
Intervention: Ceiling fan (30°C, max. 0.8 m/s, mean 0.7 m/s)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Task fan (30°C, max. 0.8 m/s, mean 0.6 m/s)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Thermally neutral (27°C, 0.2 m/s)
Number of subjects: 18
Study: 30672194

Group type: EXPERIMENTAL
Intervention: Long-time needle retaining at Baihui (GV 20)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Neurological routine treatment and western medicine rehabilitation therapy (Control)
Number of subjects: 70
Study: 26573368

Group type: EXPERIMENTAL
Intervention: Vitamin, mineral and n-3 fatty acid supplementation
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study: 24856273

Group type: EXPERIMENTAL
Intervention: iPad-assisted cognitive training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (without cognitive training)
Number of subjects: 20
Study: 22451180

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 52